Private: Gallery Post #1

19

Jun2015

QUEBEC: INESSS Upcoming Meetings with Manufacturers – February 2016 “Liste des médicaments”

INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the February 2016 “Liste des médicaments". These meetings will be held between August 28 and September 11, 2015, inclusively. Meetings will cover the following: Discussion on clinical studies Discussion ... Read More

12

Jun2015

QUÉBEC – INESSS Submission Deadlines: 2015-2016

The Minister of Health and Social Services has authorized three updates to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2016: February 1, June 1 and October 3, 2016. Updates to the lists of medications for multisource generic ... Read More

08

Jun2015

PDCI International Trends Series Part 5

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were public and private payers, and industry stakeholders in both Canada and Europe. The final issue in this series reveals stakeholder’s perspectives on exclusivity agreements in ... Read More

27

May2015

BC: Updates to BC Drug Review Process and Submission Requirements

The BC Ministry of Health recently wrote to manufacturers to communicate updates to its drug review process and reimbursement submission requirements. Updates to the Drug Review Process include: The Drug Benefit Council (DBC) will now screen drug submissions under review by CDR to determine if a full DBC review is necessary. If ... Read More

27

May2015

ON: Amendments to Ontario Regulation 201/96

The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April ... Read More

26

May2015

PDCI International Trends Series Part 4

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada. The current issue presents the perspectives of stakeholders on the biosimilar market.  Recent experience in Norway ... Read More

25

May2015

Canadian Organization for Rare Disorders (CORD) to release first ever Rare Disease Strategy

The Canadian Organization for Rare Disorders (CORD) announced Friday that it will help launch Canada's first ever Rare Disease Strategy on Monday, May 25th, at 10am in Ottawa on Parliament Hill. This Strategy was prepared by CORD further to extensive consultations over the past year with various stakeholders, with input from patients, ... Read More

19

May2015

PDCI International Trends Series Part 3

PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada.  The current issue presents the perspectives of both private and public payers, and industry representatives ... Read More

14

May2015

PDCI International Trends Series Part 2

PDCI Market Access recently launched the International Trends Series, which provides the results of an online survey PDCI conducted between March 19, 2015 and March 25, 2015. Participants were stakeholders in Europe and Canada.  The first issue, “Delisting of Oncology Treatments” was released last week. This current issue reveals the ... Read More

04

May2015

PDCI International Trends Series

In preparation for the recent Pharma Symposium conference held in Toronto on March 31-April 1, PDCI conducted an online survey of a select group of pharmaceutical stakeholders in Canada and Europe.  The purpose of this survey was to gauge whether some of the cost containment mechanisms being implemented in certain ... Read More